Pregnancy Loss and Cancer Risk:A Nationwide Observational Study by Mikkelsen, Anders P et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Pregnancy Loss and Cancer Risk
A Nationwide Observational Study
Mikkelsen, Anders P; Egerup, Pia; Ebert, Julie F M; Kolte, Astrid M; Nielsen, Henriette S.;
Lidegaard, Øjvind
Published in:
EClinicalMedicine
DOI:
10.1016/j.eclinm.2019.08.017
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Mikkelsen, A. P., Egerup, P., Ebert, J. F. M., Kolte, A. M., Nielsen, H. S., & Lidegaard, Ø. (2019). Pregnancy
Loss and Cancer Risk: A Nationwide Observational Study. EClinicalMedicine, 15, 80-88.
https://doi.org/10.1016/j.eclinm.2019.08.017
Download date: 23. Jun. 2020
EClinicalMedicine 15 (2019) 80–88
Contents lists available at ScienceDirect
EClinicalMedicine
journal homepage: www.elsevier.com/locate/eclinm
Research Paper
Pregnancy Loss and Cancer Risk: A Nationwide Observational Study
Anders P. Mikkelsena,∗, Pia Egerupb, Julie F.M. Eberta, Astrid M. Kolted,
Henriette S. Nielsenc,d, Øjvind Lidegaarda
aDepartment of Gynaecology and Obstetrics 4232, Copenhagen University Hospital Rigshospitalet, Denmark
bDepartment of Clinical Oncology, Zealand University Hospital, Roskilde, Denmark
c Fertility Clinic 4071, Copenhagen University Hospital Rigshospitalet, Denmark
d The Recurrent Pregnancy Loss Unit, Fertility Clinic 4071, Copenhagen University Hospital Rigshospitalet, Denmark
a r t i c l e i n f o
Article history:
Received 3 June 2019
Revised 27 August 2019
Accepted 27 August 2019
Available online 9 October 2019
a b s t r a c t
Background: Cancer is the second leading cause of death worldwide. Few studies have investigated if
recurrent pregnancy loss is associated with an increased risk of cancer. We aimed to assess whether
pregnancy loss is associated with later cancer development.
Methods: We identified all invasive cancers after age 40, among all Danish women born between January
1957 and December 1972, ensuring a full reproductive history. Cases were matched by birth year 1:10
to cancer-free controls. Women were followed until the end of 2017. The number of pregnancy losses
(miscarriages or still births) was correlated to long-term cancer risk using conditional logistic regression,
providing odds ratios for specific cancers with different numbers of pregnancy losses, all adjusted for age,
education, and other potential confounders.
Findings: The study included 28,785 women with cancer (mean age 48.7 [SD 5.0]) and 283,294 matched
controls (mean age 48.6 [SD 5.0]). We found no overall association between pregnancy loss and later
development of 11 site-specific types of cancer or cancer overall. Taking the sequence of pregnancy losses
into account, primary recurrent pregnancy loss (three consecutive pregnancy losses without prior live
birth) was associated with later overall cancer by an odds ratio of 1.27 (1.04–1.56). Secondary recurrent
pregnancy loss showed no association to cancer.
Interpretation: Pregnancy loss was not associated with later cancer development. Women with primary
recurrent pregnancy loss had a borderline significant association to later cancer overall, this may be a
chance finding.
Funding: Ole Kirk’s Foundation and Copenhagen University Hospital Rigshospitalet’s Research Grant.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Research in Context
Evidence Before This Study
We searched PubMed for relevant studies published be-
fore Feb 1, 2019 for associations between pregnancy loss and
cancer. The following search phrases were used: “pregnancy
loss”, “abortion”, or “miscarriage”; and “cancer”. Articles were∗ Corresponding author.
E-mail addresses: anders.mikkelsen@regionh.dk (A.P. Mikkelsen),
piaegerup@hotmail.com (P. Egerup), julie_ebert@icloud.dk (J.F.M. Ebert),
astrid.marie.kolte@regionh.dk (A.M. Kolte), henriette.svarre.nielsen@regionh.dk
(H.S. Nielsen), oejvind.lidegaard@regionh.dk (Ø. Lidegaard).
https://doi.org/10.1016/j.eclinm.2019.08.017
2589-5370/© 2019 Published by Elsevier Ltd. This is an open access article under the CCcritically assessed for relevance by the first author. No lan-
guages were excluded from our search.
The association between pregnancy loss and breast can-
cer has been summarized in two meta-analyses including 59
studies; they found no positive correlation. Two contradict-
ing studies investigated the outcome of ovarian cancer, one
found an increased risk while the other did not. However,
out of these 61 studies none reported the effect of recurrent
pregnancy loss, 49 relied on self-reported data, and most did
not report the number of pregnancy losses hiding a potential
dose–response relationship. One study investigating the influ-
ence of recurrent pregnancy loss (RPL) on the risk of later
cancer development, found an increased risk of breast cancer
and cancer overall as compared to women without RPL.
RPL is of specific interest as the frequency of euploid
losses increases, with increasing number of pregnancy losses,BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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tpointing to non-fetal causes. Furthermore, women with RPL
have been found to have an increased risk of myocardial in-
farction and stroke later in life.
Added Value of This Study
This study is the first to examine both the number of
pregnancy losses, and the influence of consecutive or non-
consecutive pregnancy loss patterns, on the risk of 11 site-
specific types of cancer and on cancer overall. Our study
finds no strong association between pregnancy loss and later
cancer development, thereby contradicting the study which
found RPL to be a risk factor for later cancer.
Implications of All the Available Evidence
Pregnancy loss is not associated with an increased risk of
cancer later in life, taking this potential burden from women
already struggling to achieve a live birth.
. Introduction
Reproductive factors have repeatedly been associated with dif-
erent cancers. Young age at first full-term pregnancy lowers the
ong-term risk of breast cancer [1,2], however, postpartum the
hort-term risk of breast cancer is increased [3]. Each childbirth
educes the risk of ovarian and endometrial cancer. As cancer is a
ajor contributor to morbidity and mortality worldwide, identify-
ng groups at risk is essential for early detection of disease.
Pregnancy loss is the most common serious complication in
arly pregnancy, and at least one in three pregnancies end in a loss
4]. Pregnancy loss has been positively correlated to future risk of
yocardial infarction, cerebral infarction [5,6], hypertension, type 2
iabetes, and hypercholesterolemia [7], although the etiology and
ignificance are largely unknown.
Most studies have focused on pregnancy loss as a dichotomous
xposure (ever/never) and later risk of breast cancer, and ovarian
ancer. Results from most of these studies indicate no association
8–10], although some find a positive correlation [11,12].
Recurrent pregnancy loss is most often defined as three consec-
tive pregnancy losses and affects 1–2% of women trying to con-
eive [13], and of those referred to a tertiary center, two thirds
ave at least one live birth within five years [14]. Few studies have
xamined consecutive pregnancy losses as a possible risk indicator
or later cancer. A recent study found two consecutive pregnancy
osses to be positively associated with future breast and cervical
ancer [15].
The aim of this study was to investigate if pregnancy loss is
ssociated with cancer. Immunological mechanisms are known to
lay a role in specific types and successions of pregnancy loss [16–
0], as well as in preventing different types of cancer [21]. There-
ore, we examined exposure to these subtypes of pregnancy loss
nd their correlation to subsequent cancer development.
. Methods
.1. Sources of Data
Denmark has a free and universal public healthcare system.
ince the founding of the Danish Civil Registration System in
968, all individuals living in Denmark have been registered in
his database with their permanent 10-digit personal identification
umber, marital status, vital status, kinship information, and past
nd present addresses. The personal identification number is used
or contacts with essentially any Danish government agency, in-luding hospital visits and purchase of prescription medicine. Sup-
lementary Table S1 describes the registries used in this study;
upplementary Table S1 shows all the codes we searched for in
hese registries to define baseline characteristics, exposures and
utcomes. Discharge diagnoses were coded using the International
lassification of Diseases 8th revision before 1994, thereafter the
0th revision. Prescription medicine was coded using the Anatom-
cal Therapeutic Chemical Classification System.
The Danish Health Registry, established in 1976, and the Danish
edical Birth Registry, established in 1973, provided registry-based
ollow-up of exposures and covariates for all Danish women. Can-
er events (cases) were primarily identified in the Danish Cancer
egistry, with virtually complete data on cancer diagnoses from
987 throughout 2016, verified with pathology testing [22]. For
017, data on cancer outcomes was provided by the Danish Health
egistry, as data from 2017 was not yet available in the Danish
ancer Registry at the time of data extraction. All diagnoses and
urgical codes were made by clinicians; pre-pregnancy weight and
moking status were self-reported. The gestational week of miscar-
iages has been registered since 1995.
.2. Design
A nationwide cohort study with a case–control analysis.
.3. Study Population
To ensure a full reproductive history, we included women born
etween January 1st, 1957 and December 31st, 1972 as they were
etween 5 and 20years old when a full registry-based follow-up
as possible from 1977. Supplementary Fig. S1 provides a Lexis di-
gram illustrating the selection of the study population.
Cases were women with a first-time invasive cancer, subdivided
y site-specific cancer type: (i) breast, (ii) ovarian, (iii) endome-
rial, (iv) cervical, (v) bladder, (vi) renal, (vii) lung, (viii) gastro-
ntestinal, (ix) brain, (x) hematological, (xi) melanoma, and (xii)
ll-type cancer, except non-melanoma skin cancer. To evaluate the
ffect of events occurring throughout the reproductive age on later
isk of cancer, we excluded women with first-time cancer before
0 years of age. The earliest calendar year an outcome of interest
ould occur was therefore 1997, while the latest was 2017. Controls
ere sampled at random from all Danish female residents, using
he Danish Civil Registration System, matching each case by birth
ear to 10 controls alive at the event date, using exact matching.
he index date for cases was the date of cancer diagnosis, while
or controls the index date was the date of cancer for the case
hey were specifically matched to. Both cases and controls were
xcluded if they resided outside of Denmark for over six months
etween their 20th birthday and the index date, as they potentially
ould have had unregistered pregnancies or cancers abroad.
.4. Exposures
The primary exposure of interest was one or more pregnancy
osses, defined as either a miscarriage or a still birth. Miscar-
iages were identified in the Danish Health Registry and stillbirths
ere identified in the Danish Medical Birth Registry. Women ever-
regnant (i.e. one or more registered miscarriage, termination of
regnancy, still birth or live birth) were at the index date strati-
ed to one of the following exposure groups: 0 pregnancy losses,
ne pregnancy loss, two pregnancy losses or, three or more preg-
ancy losses. In addition to the number of pregnancy losses, we
lso examined specific a priori defined subtypes of pregnancy loss,
nown or hypothesized to be associated with immunological dis-
urbances: (i) Three pregnancy losses before 30 years of age, (ii)
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nancy loss (three consecutive pregnancy losses not preceded by a
live birth), (iv) Secondary recurrent pregnancy loss (three consec-
utive pregnancy losses preceded by a live birth), (v) Three consec-
utive pregnancy losses preceded by a pregnancy complicated by
either preterm birth, intrauterine growth restriction, preeclampsia
or placental abruption, (vi) Two second trimester pregnancy losses,
and (vii) A still birth. Besides three consecutive registered preg-
nancy losses, a diagnosis of recurrent pregnancy loss was also con-
sidered as three consecutive pregnancy losses. Finally, we investi-
gated the impact of never-pregnant (i.e. no registered miscarriage,
termination of pregnancy, still birth or live birth) on cancer risk,
with ever-pregnant as reference group.
2.5. Confounders
We considered baseline characteristics seen in Table 1. Data was
provided using the aforementioned registries, in addition to the
Danish Registry of Medicinal Product Statistics (the Prescription
Registry). We adjusted for the following potential confounders in
all adjusted analyses: attained age at index date (continuous vari-
able) and educational level of a bachelor’s degree or higher (binary
variable). Breast cancer was further adjusted for parity (indicator
variable), age under 30 at first live birth (binary variable), and
ever/never use of systemic hormonal contraception (binary vari-
able). Ovarian cancer was adjusted for parity and ever/never use of
systemic hormonal contraception. Endometrial cancer was adjusted
for parity, ever/never use of systemic hormonal contraception, and
diabetes (binary variable). Diabetes and use of systemic hormonal
contraception were identified by drug purchases in the Prescription
Registry, available from 1995 to 2014 at the time of data extrac-
tion. Pre-pregnancy smoking habits and pre-pregnancy body mass
index were registered in the Danish Medical Birth Registry from
year 1991 to 2004, respectively, thus resulting in missing values
for women with only live births before these dates or women with
no live births. A sensitivity analysis further adjusting for ever/never
smoking (binary variable) was calculated for the lung cancer out-
come for those with this data available. Likewise, a sensitivity anal-
ysis further adjusting for ever/never body mass index >30 (binary
variable) was calculated for the outcome of gastro-intestinal can-
cer.
2.6. Statistical Analyses
Numerical baseline characteristics were described by a mean
and standard deviation, and differences between case and con-
trol groups were tested using the Mann–Whitney U test. Binary
variables were described by proportions, and differences between
cases and controls were calculated using Pearson’s χ 2-test. A p-
value <0.05 was considered statistically significant. The measure of
association between exposure and outcome variables was an odds
ratio, calculated using conditional logistic regression. Results were
presented with 95% confidence intervals. Programming and statis-
tical analyses were performed in SAS software version 9.4 (SAS In-
stitute), Stata software version 15 (StataCorp LLC) and R version 3.5
(The R Foundation for Statistical Computing).
The Danish Health Data Authority approved access to registry
data. No ethical approval was required.
3. Results
The study included 28,785 women with incident invasive can-
cer and 283,294 matched cancer-free controls (Fig. 1 ). The over-
all mean age was 48.6 years at the index date (standard devia-
tion 5.0 years). The most common site-specific cancers were breastancer (42.3%), melanoma (11.6%), and gastro-intestinal cancer
11.0%).
Although most differences between cases and controls were mi-
or, some were notable (Table 1): Educational level was lower
mong all cancer groups, except for the melanoma group. Com-
aring cases to controls: fewer women with breast cancer had
iven birth before age 30, fewer women with gynecological can-
ers had ever used systemic hormonal contraception, more women
ith endometrial cancer and renal cancer had diabetes, and previ-
us induced abortion was more prevalent in the cervical cancer
roup.
Among ever-pregnant women with 0 pregnancy losses as ref-
rence group, we generally found no correlation between the
umber of pregnancy losses and later cancer risk (Table 2). Ad-
usting for potential confounders only changed our estimates
arginally. Endometrial cancer showed a non-significant inverse
ssociation with three or more pregnancy losses, correlated by
n adjusted odds ratio of 0.75 (0.34–1.66). Likewise, melanoma
isplayed an inverse association, however, only two pregnancy
osses and not three or more was significantly associated with
decreased melanoma risk, adjusted odds ratio 0.72 (0.57–0.90)
nd 0.69 (0.47–1.01), respectively. Renal cancer and hematological
ancer displayed a positive non-significant association with preg-
ancy loss, with exposure to three or more pregnancy losses cor-
elated to renal cancer by an adjusted odds ratio of 1.97 (0.90–
.28) and to hematological cancer by an adjusted odds ratio of 1.43
0.90–2.25).
For the different subtypes of pregnancy loss among ever-
regnant women (Table 3) we found few significant associations:
he exposure to three pregnancy losses before age 30 was pos-
tively correlated to later lung cancer; adjusted odds ratio 2.22
1.28–3.86). In a sensitivity analysis further adjusting for tobacco
moking, the association was weakened and no longer significant
Supplementary Table S3). Two second trimester pregnancy losses
onferred an adjusted odds ratio of 4.00 (1.38–11.60) for hema-
ological cancers. Women with recurrent pregnancy loss had an
djusted odds ratio for gastro-intestinal cancer of 1.37 (0.91–2.07)
nd of 1.15 (0.99–1.32) for all cancers (Fig. 2 ). Stratifying this expo-
ure into primary or secondary recurrent pregnancy loss, only pri-
ary recurrent pregnancy loss was associated with the two cancer
roups; odds ratios 2.00 (1.16–3.45) and 1.27 (1.04–1.56), respec-
ively. Similarly, exposure to three pregnancy losses before age 30
as associated with gastro-intestinal cancer; adjusted odds ratio
.86 (1.11–3.11).
In Supplementary Table S4 we focused on the exposure to re-
urrent pregnancy loss and subdivided our population according
o the age at cancer diagnosis, over or under 50 years of age. We
ound that exposure to recurrent pregnancy loss confers a statis-
ically significant increased odds ratio of gastro-intestinal cancer
adjusted odds ratio 1.92 [1.11–3.26]), hematological cancer (odds
atio 1.97 [1.02–3.80]) and cancer overall (adjusted odds ratio 1.20
1.01–1.44]), between ages 40 and 49, but not in the age group 50–
1. In contrast, exposure to recurrent pregnancy loss had a ten-
ency towards an increased odds ratio of gynecological cancers in
he age group 50–61 compared to the younger age group, however,
his was not statistically significant.
Never being pregnant was positively associated with later ovar-
an cancer; adjusted odds ratio 1.72 (1.43–2.06), endometrial can-
er; 2.92 (2.49–3.43) and inversely associated with melanoma and
reast cancer; adjusted odds ratio 0.88 (0.78–0.99) and 0.94 (0.88–
.00), respectively (Supplementary Table S5).
In the analysis for gastro-intestinal cancer and cancer overall,
e further adjusted for body mass index ≥30 in the subgroup of
atients with weight data available (6.0%). This had very little ef-
ect on the results (Supplementary Table S6).
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Table 1
Characteristics of cancer cases and controls at the index date according to cancer type.
Cases Controls Cases Controls Cases Controls
Breast cancer Ovarian cancer Endometrial cancer
n 12,181 120,136 901 8857 982 9598
Mean age (SD) - yr 48.4 (4.7) 48.5 (4.7) 48.5 (4.7) 48.4 (4.7) 48.5 (5.0) 48.5 (5.0)
Parity (SD) 1.8 (1.0) 1.9 (1.1) 1.6 (1.1) 1.9 (1.1)∗ 1.4 (1.1) 1.9 (1.1)∗
Age under 30 at first live birth - % 64.4 67.7∗ 62.2 68.1∗ 56.0 68.6∗
Previous induced abortion - % 28.3 28.6 27.0 28.5 19.8 28.1∗
Diabetes Mellitus - % 2.5 3.2∗ 4.3 3.2 10.0 3.2∗
Asthma - % 2.6 2.9 3.2 2.7 2.6 2.8
Inflammatory bowel disease - % 1.4 1.4 2.0 1.3 1.4 1.7
Systemic hormonal contraception, ever use - % 54.9 52.5∗ 40.2 50.0∗ 35.6 48.7∗
Educational level of bachelor’s degree or higher - % 29.0 29.4 20.5 29.4∗ 27.1 29.0
Body-Mass Index ≥30 - %a 8.2 13.6∗ 13.9 14.3 17.7 13.5
Smoking - % b 31.8 31.1 35.1 31.1 24.4 30.6
Cervical cancer Bladder cancer Renal cancer
n 1282 12,670 183 1780 393 3860
Mean age (SD) - yr 45.6 (4.6) 45.5 (4.6) 50.2 (4.9) 49.9 (4.8) 49.9 (5.0) 49.8 (5.0)
Parity (SD) 1.8 (1.2) 1.9 (1.1)∗ 1.7 (1.2) 1.9 (1.1)∗ 2.0 (1.1) 1.9 (1.1)
Age under 30 at first live birth - % 66.0 67.1 67.8 68.5 74.3 68.1
Previous induced abortion - % 32.6 28.8∗ 32.8 27.8 30.3 28.9
Diabetes Mellitus - % 2.4 3.1 4.4 3.5 9.4 3.0∗
Asthma - % 1.5 2.5∗ 3.3 2.9 3.6 2.9
Inflammatory bowel disease - % 2.1 1.4∗ <5 1.4 2.8 1.3∗
Systemic hormonal contraception, ever use - % 55.9 56.5 52.5 50.3 51.2 51.8
Educational level of bachelor’s degree or higher - % 21.5 30.5∗ 13.7 28.0∗ 17.1 30.3∗
Body-Mass Index ≥30 - %a 16.1 13.2 <5 9.8 37.5 15.4∗
Smoking - %b 41.5 30.5∗ 54.2 30.5∗ 49.2 29.8∗
Lung cancer Gastro-intestinal cancer Brain cancer
n 2095 20,533 3154 30,834 398 3890
Mean age (SD) - yr 50.7 (4.8) 50.6 (4.8) 50.0 (5.0) 50.0 (5.0) 48.2 (5.3) 48.1 (5.4)
Parity (SD) 1.8 (1.1) 1.8 (1.1)∗ 1.8 (1.1) 1.9 (1.1)∗ 1.9 (1.1) 1.8 (1.1)
Age under 30 at first live birth - % 72.0 68.7∗ 66.4 68.1 68.6 67.6
Previous induced abortion - % 34.3 28.3∗ 29.4 28.5 28.4 28.6
Diabetes Mellitus - % 4.7 3.4∗ 6.0 3.3∗ 2.0 3.1
Asthma - % 4.8 2.9∗ 2.9 2.9 5.0 2.7∗
Inflammatory bowel disease - % 1.6 1.3 2.2 1.4∗ 2.3 1.5
Systemic hormonal contraception, ever use - % 50.1 47.0∗ 49.0 49.9 56.5 51.8
Educational level of bachelor’s degree or higher - % 5.8 28.1∗ 16.5 29.2∗ 12.1 28.4∗
Body-Mass Index ≥30 - %a 14.3 12.5 19.4 12.9∗ 8.3 10.7
Smoking - %b 79.2 31.4∗ 39.1 31.0∗ 37.3 31.1
Hematological cancer Melanoma All cancersc
n 1341 13,250 3339 32,974 28,785 283,294
Mean age (SD) - yr 49.3 (5.2) 49.2 (5.2) 47.4 (4.8) 47.3 (4.8) 48.7 (5.0) 48.6 (5.0)∗
Parity (SD) 1.8 (1.1) 1.9 (1.1)∗ 1.8 (1.0) 1.9 (1.1) 1.8 (1.1) 1.9 (1.1)∗
Age under 30 at first live birth - % 65.8 67.4 65.5 67.2∗ 65.5 67.8∗
Previous induced abortion - % 30.8 28.3 26.7 28.2 28.8 28.4
Diabetes Mellitus - % 4.3 3.2 2.8 3.0 3.8 3.2∗
Asthma - % 3.4 3.1 2.5 2.9 2.9 2.9
Inflammatory bowel disease - % 1.9 1.3 1.7 1.4 1.7 1.4∗
Systemic hormonal contraception, ever use - % 50.5 51.8 59.7 57.0∗ 24.1 29.4∗
Educational level of bachelor’s degree or higher - % 23.6 29.7∗ 32.6 30.0∗ 24.1 29.1∗
Body-Mass Index ≥30 - %a 11.1 12.3 7.6 12.9∗ 11.1 13.4∗
Smoking - %b 35.4 30.9∗ 25.6 31.2∗ 35.8 31.1∗
(Notice the number of cases and controls in ’All cancers’ is greater than the subgroups combined as other types of cancer were included.)
SD: Standard Deviation.
<5: Data not available for presentation due to less than five observations.
∗ Indicates a p-value of <0.05 between the case and control group.
a Information only available for 6.0% of all patients.
b Information only available for 53.5% of all patients.
c All types of cancer, except non-melanoma skin cancer.
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In this nationwide observational study of 28,785 women with
ncident invasive cancer and a full registry-based reproductive his-
ory, we found no evidence of an overall association between num-
er of pregnancy losses and later cancer development. Among
hose exposed to subtypes of pregnancy loss correlated to im-
unological mechanisms, we found sporadic associations to laterancer, however, we found no clear trend indicating a robust posi-
ive association to site-specific cancers or cancer in general.
.1. Pregnancy Loss and Cancer Risk
Two meta-analyses on the association between pregnancy loss
nd breast cancer have been published. The first by the Collab-
rative Group on Hormonal Factors in Breast Cancer published in
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Fig. 1. Flow chart showing the selection of cases for the study. The sum of the subtypes of cancers does not add up to the total case population as 8.7% develop other types
of cancer.
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p2004 [8], included 52 studies. Of these, 12 studies recorded preg-
nancy loss in a prospective manner (i.e. before the cancer diagno-
sis). Among the prospective studies, eight studies relied on self-
reported data. Only two prospective studies relying on hospital
records, reported the number of pregnancy losses more specifi-
cally than ever/never, these evaluated 482 cancer cases [23,24].
The second meta-analysis by Guo et al. included no new studies
with non-self-reported data on pregnancy loss [9]. None of the
included studies evaluated the effect of consecutive losses. Both
meta-analyses found no association between pregnancy loss and
breast cancer, which is in accordance with our findings.
To our knowledge, the only other study investigating recur-
rent pregnancy loss and subsequent risk of cancer is the study by
Charach et al. [15]. They found a significantly increased risk of cer-
vical cancer (odds ratio 1.6, p-value 0.038), breast cancer (odds ra-
tio 1.7, p-value 0.001), and female malignancy overall with an ad-
justed hazard ratio of 1.35 (95% confidence interval 1.1–1.6). The
study included cases at their first pregnancy after a recurrent preg-
nancy loss defined as two or more consecutive pregnancy losses,
uhile controls were included at a random pregnancy. Cases were
herefore on average 2.52 years older, p-value <0.001 and this age
ifference was apparently not adjusted for in the analyses.
.2. Special Pregnancy Loss Groups
Among pregnancy losses in the first trimester, 50–70% have
een found to have fetal chromosomal abnormalities [25,26]. With
ultiple first trimester pregnancy losses the proportion of euploid
osses increases [27]. The underlying pathophysiology behind the
uploid pregnancy losses is largely unknown. Some may be due to
enetic errors of the fetus such as microdeletions, point mutations,
pigenetic changes, and structural abnormalities, while others may
e caused by maternal factors, including uterine, coagulative, en-
ocrine, and immunological disturbances [16–20].
Known risk factors for pregnancy loss and recurrent pregnancy
oss include: increasing maternal age, previous pregnancy loss,
arental genetic abnormalities, polycystic ovarian syndrome, coag-
lative disorders, endocrine diseases such as thyroid disease and
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Table 2
Association between number of pregnancy losses and cancer in ever-pregnant women.
Cases Controls OR ORadj (95%CI) Cases Controls OR ORadj (95%CI)
Breast cancer Ovarian cancer
n 10,918 107,009 736 7847
0 PL 8411 (77.0) 82,045 (76.7) 1 1 581 (78.9) 6098 (77.7) 1 1
1 PL 1926 (17.6) 19,362 (18.1) 0.97 0.98 (0.93–1.04) 113 (15.4) 1360 (17.3) 0.86 0.86 (0.69–1.07)
2 PL 424 (3.4) 4046 (3.4) 1.01 0.99 (0.89–1.10) 32 (4.4) 292 (3.7) 1.11 1.18 (0.80–1.72)
≥3 PL 157 (1.4) 1556 (1.5) 0.97 0.97 (0.81–1.16) 10 (1.4) 97 (1.2) 1.06 1.11 (0.56–2.17)
Endometrial cancer Cervical cancer
n 734 8608 1123 11,270
0 PL 580 (79.0) 6588 (76.5) 1 1 878 (78.2) 8616 (76.5)) 1 1
1 PL 125 (17.0) 1570 (18.2) 0.92 0.93 (0.76–1.15) 195 (17.4) 2045 (18.2) 0.94 0.95 (0.80–1.11)
2 PL 22 (3.0) 333 (3.9) 0.70 0.69 (0.44–1.09) 35 (3.1) 435 (3.0) 0.77 0.78 (0.55–1.12)
≥3 PL 7 (1.0) 117 (1.4) 0.78 0.75 (0.34–1.66) 15 (1.3) 174 (1.5) 0.88 0.90 (0.53–1.54)
Bladder cancer Renal cancer
n ~155 1585 360 3453
0 PL 124 (79.5) 1200 (75.7) 1 1 257 (71.4) 2662 (77.1) 1 1
1 PL 24 (15.4) 299 (18.9) 0.80 0.83 (0.52–1.32) 76 (21.1) 614 (17.8) 1.27 1.31 (0.99–1.73)
2 PL 7 (4.5) 70 (4.4) 1.08 1.24 (0.54–2.81) 19 (5.3) 138 (4.0) 1.37 1.39 (0.83–2.34)
≥3 PL <5 16 (1.0) n/a n/a 8 (2.2) 39 (1.1) 1.94 1.97 (0.90–4.28)
Lung cancer Gastro–intestinal cancer
n 1857 18,244 2774 27,421
0 PL 1424 (76.7) 13,951 (76.5) 1 1 2149 (77.5) 21,009 (76.6) 1 1
1 PL 341 (18.4) 3303 (18.1) 1.03 1.08 (0.95–1.23) 482 (17.4) 4981 (18.2) 0.93 0.95 (0.85–1.05)
2 PL 64 (3.5) 717 (3.9) 0.86 0.91 (0.69–1.19) 105 (3.8) 1075 (3.9) 0.95 0.98 (0.79–1.20)
≥3 PL 28 (1.5) 273 (1.5) 1.04 1.03 (0.69–1.54) 38 (1.4) 356 (1.3) 1.06 1.08 (0.76–1.53)
Brain cancer Haematological cancer
n 359 3452 1182 11,787
0 PL 280 (78.0) 2685 (77.8) 1 1 898 (76.0) 9020 (76.5) 1 1
1 PL 58 (16.2) 583 (16.9) 0.94 0.93 (0.69–1.26) 213 (18.0) 2145 (18.2) 1.01 1.01 (0.86–1.19)
2 PL 12 (3.3) 141 (4.1) 0.83 0.81 (0.44–1.50) 49 (4.2) 465 (4.0) 1.07 1.06 (0.78–1.44)
≥3 PL 9 (2.5) 43 (1.3) 2.09 1.96 (0.93–4.12) 22 (1.9) 157 (1.3) 1.43 1.43 (0.90–2.25)
Melanoma All cancersa
n 2360 22,477 25,420 252,218
0 PL 2360 (78.3) 22,477 (76.6) 1 1 19,591 (77.1) 193,340 (76.7) 1 1
1 PL 538 (17.8) 5308 (18.1) 0.96 0.96 (0.87–1.06) 4506 (17.7) 45,660 (18.1) 0.98 0.98 (0.95–1.02)
2 PL 87 (2.9) 1149 (3.9) 0.72 0.72 (0.57–0.90) 963 (3.8) 9671 (3.8) 0.98 0.98 (0.92–1.05)
≥3 PL 30 (1.0) 411 (1.4) 0.70 0.69 (0.47–1.01) 359 (1.4) 3547 (1.4) 1.01 1.02 (0.91–1.14)
Bold font signifies a statistically significant result with regard to the 95% confidence interval (CI).
OR: Crude odds Ratio, confidence interval not shown due to size of table. ORadj: Odds Ratio, adjusted for age and attainment of bachelor’s
degree. Breast cancer additionally adjusted for parity, age at first live birth and hormonal contraception ever/never use. Ovarian cancer ad-
ditionally adjusted for parity and hormonal contraception ever/never use. Endometrial cancer adjusted for parity, hormonal contraception
ever/never use, and diabetes.
<5: Data not available for presentation due to less than five observations, estimate therefore not available (n/a), and total n rounded to
nearest 5.
a All invasive cancers, except non-melanoma skin cancer. PL: Pregnancy loss (miscarriage or still birth).
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4iabetes. More euploid losses are seen with high body mass index
28]. Life style factors such as alcohol consumption and smoking,
ppear to increase the risk of pregnancy loss in a dose–response
anner [29]. However, the prognostic significance of the majority
f hitherto identified risk factors remains largely unknown, and the
hance of subsequent live birth is still based on maternal age and
umber of prior pregnancy losses [30].
We investigated specific a priori defined exposure subgroups
reviously shown to be correlated to immunological mechanisms
nd have a high risk of euploid loses (Table 3). Exposure to primary
ecurrent pregnancy loss showed the strongest association to can-
er, driven primarily by an increased risk of gastro-intestinal can-
er and hematological cancer. In the main analysis this was only
ignificantly associated with the overall cancer, however, in a sen-
itivity analysis further stratifying according to age at cancer (Sup-
lementary Table S4), the odds of these cancers was almost dou-
led at ages 40–49years. The specific reasons for the modest in-
rease in cancer risk among the primary recurrent pregnancy loss
roup, cannot be explained by the current study, however, our hy-
potheses include: A common precursor (e.g. a gene or environ-
ental factor) increasing a woman’s risk of both recurrent preg-
ancy loss and cancer. Another possibility is that exposure to re-
urrent pregnancy loss increases the risk of later cancer, by a me-
iating factor such as changes in life style or possibly by disturbing
he maternal immune system, and crucially the ability to recognize
recursors to cancer. However, we cannot rule out that the result
rose from a chance finding, due to the nature of a 95% confidence
nterval, therefore reproducing our results in other populations is
arranted.
Other statistically significant results were seen, e.g. three or
ore pregnancy losses before age 30 was associated with gastro-
ntestinal cancer and two pregnancy losses in the second trimester
as positively associated with hematological cancer.
.3. Never-pregnant
The group of women with no registered pregnancies likely com-
rises a heterogenic group, with two very different subgroups; the
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Table 3
Association between subtypes of pregnancy loss and cancer in ever-pregnant women.
Cases Controls ORadj (95% CI) Cases Controls ORadj (95% CI)
Breast cancer Ovarian cancer
n 10,918 107,009 736 7847
RPL 105 (1.0) 889 (0.8) 1.10 (0.88–1.37) 8 (1.1) 55 (0.7) 1.62 (0.75–3.48)
Primary RPL 54 (0.5) 379 (0.4) 1.01 (0.96–1.07) <5 19 (0.2) n/a
Secondary RPL 51 (0.5) 510 (0.5) 0.98 (0.73–1.32)) <5 36 (0.5) n/a
RPL after a complicated deliveryb 10 (0.1) 61 (0.1) 1.86 (0.94–3.70) <5 10 (0.1) n/a
≥3 PL before age 30 42 (0.4) 427 (0.4) 1.04 (0.75–1.45) <5 31 (0.4) n/a
≥2 PL in 2nd. trimester 14 (0.1) 134 (0.1) 0.99 (0.54–1.80) <5 9 (0.1) n/a
≥1 still birth 79 (0.7) 1010 (0.9) 0.84 (0.66–1.07) 9 (1.2) 82 (1.0) 1.27 (0.60–2.69)
Endometrial cancer Cervical cancer
n 734 8608 1123 11,270
RPL 6 (0.8) 67 (0.8) 1.25 (0.52–3.01) 9 (0.8) 100 (0.9) 1.01 (0.51–2.02)
Primary RPL <5 26 (0.3) n/a <5 54 (0.5) <5
Secondary RPL <5 41 (0.5) n/a 7 (0.6) 46 (0.4) 1.67 (0.74–3.75)
RPL after a complicated deliveryb <5 5 (0.1) n/a <5 6 (0.1) <5
≥3 PL before age 30 <5 26 (0.3) n/a 6 (0.5) 64 (0.6) 0.92 (0.39–2.15)
≥2 PL in 2nd. trimester <5 9 (0.1) n/a <5 19 (0.2) <5
≥1 still birth 7 (1.0) 89 (1.0) 1.03 (0.43–2.45) 16 (1.4) 121 (1.1) 1.26 (0.74–2.14)
Bladder cancer Renal cancer
n 156 1585 360 3453
RPL <5 11 (0.7) n/a <5 14 (0.4) n/a
Primary RPL <5 6 (0.4) n/a <5 9 (0.3) n/a
Secondary RPL <5 5 (0.3) n/a <5 5 (0.1) n/a
RPL after a complicated deliveryb <5 <5 n/a <5 <5 n/a
≥3 PL before age 30 <5 <5 n/a <5 10 (0.3) n/a
≥2 PL in 2nd trimester <5 <5 n/a <5 <5 n/a
≥1 still birth <5 14 (0.9) n/a 5 (1.4) 37 (1.1) 1.32 (0.51–3.41)
Lung cancer Gastro–intestinal cancer
n 1857 18,244 2774 27,421
RPL 12 (0.7) 145 (0.8) 0.88 (0.48–1.62) 28 (1.0) 207 (0.8) 1.37 (0.91–2.07)
Primary RPL 6 (0.3) 61 (0.3) 1.26 (0.53–3.01) 16 (0.6) 88 (0.3) 2.00 (1.16–3.45)
Secondary RPL 6 (0.3) 84 (0.5) 0.68 (0.30–1.58) 12 (0.4) 119 (0.4) 0.94 (0.50–1.76)
RPL after a complicated deliveryb <5 8 (0.04) n/a <5 14 (0.1) n/a
≥3 PL before age 30 17 (0.9) 77 (0.4) 2.22 (1.28–3.86) 19 (0.7) 99 (0.4) 1.86 (1.11–3.11)
≥2 PL in 2nd trimester <5 15 (0.1) n/a <5 22 (0.1) n/a
≥1 still birth 25 (1.4) 176 (1.0) 1.32 (0.86–2.04) 28 (1.0) 256 (1.0) 1.13 (0.76–1.68)
Brain cancer Haematological cancer
n 359 3452 1182 11,787
RPL <5 26 (0.8) n/a 14 (1.2) 91 (0.8) 1.58 (0.89–2.80)
Primary RPL <5 14 (0.4) n/a 7 (0.6) 46 (0.4) 1.62 (0.73–3.65)
Secondary RPL <5 12 (0.4) n/a 7 (0.6) 45 (0.4) 1.51 (0.68–3.39)
RPL after a complicated deliveryb <5 <5 n/a <5 5 (0.04) n/a
≥3 PL before age 30 <5 8 (0.2) n/a 7 (0.6) 52 (0.4) 1.38 (0.62–3.08)
≥2 PL in 2nd trimester <5 <5 n/a 5 (0.4) 13 (0.1) 4.00 (1.38–11.60)
≥1 still birth <5 27 (0.8) n/a 7 (0.6) 109 (0.9) 0.63 (0.29–1.36)
Melanoma All cancersa
n 2360 22,477 25,420 252,218
RPL 18 (0.6) 235 (0.8) 0.75 (0.46–1.21) 229 (0.9) 2028 (0.8) 1.15 (0.99–1.32)
Primary RPL 11 (0.4) 108 (0.4) 0.98 (0.52–1.83) 111 (0.4) 898 (0.4) 1.27 (1.04–1.56)
Secondary RPL 7 (0.2) 127 (0.4) 0.55 (0.26–1.18) 118 (0.5) 1130 (0.5) 1.05 (0.86–1.27)
RPL after a complicated deliveryb <5 15 (0.1) n/a 20 (0.1) 138 (0.1) 1.46 (0.89–2.37)
≥3 PL before age 30 7 (0.2) 107 (0.4) 0.64 (0.29–1.38) 113 (0.4) 997 (0.4) 1.12 (0.92–1.37)
≥2 PL in 2nd trimester <5 36 (0.1) n/a 33 (0.1) 280 (0.1) 1.18 (0.82–1.70)
≥1 still birth 26 (0.9) 275 (0.9) 0.92 (0.61–1.38) 230 (0.9) 2397 (1.0) 0.94 (0.83–1.09)
Bold font signifies a statistically significant result with regard to the 95% confidence interval (CI).
PL: Pregnancy loss (miscarriage or still birth) RPL: recurrent PL (3 consecutive losses not preceded by a live birth [primary] or preceded
by a live birth [secondary]) ORadj: Odds Ratio, adjusted for age and attainment of bachelor’s degree. Breast cancer additionally adjusted
for parity, age at first live birth, and hormonal contraception ever/never use. Ovarian cancer additionally adjusted for parity and hormonal
contraception ever/never use. Endometrial cancer adjusted for parity, hormonal contraception ever/never use, and diabetes.
<5: Data not available for presentation due to less than five observations, estimate therefore not available (n/a).
a All invasive cancers, except non-melanoma skin cancer.
b Preterm birth, intrauterine growth restriction, preeclampsia or placental abruption.
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Fig. 2. Odds ratios of different cancers after recurrent pregnancy loss.
Recurrent pregnancy loss defined as three or more consecutive pregnancy losses. The odds ratios were adjusted for age, calendar year, and attainment of a bachelor’s
degree. Breast cancer additionally adjusted for parity, age at first live birth, and ever/never use of hormonal contraception. Ovarian cancer additionally adjusted for parity
and ever/never use of hormonal contraception. Endometrial cancer adjusted for parity, ever/never use of hormonal contraception and diabetes. The scale of the x-axis is
logarithmic, and the dashed line signifies an Odds Ratio of 1 (no association). CI: Confidence Interval. Adj. OR: Adjusted Odds Ratio.
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Doluntary and the involuntarily childless. The latter is likely to
nclude chronically ill and/or infertile women. We found a posi-
ive association between the group never-pregnant and later ovar-
an cancer and endometrial cancer, which is in accordance with
revious findings [31]. The inverse association between the never-
regnant group and breast cancer was, although weak, surprising,
s previous studies have demonstrated nulliparity to increase the
isk. However, as our study population was relatively young with a
ean age of 48.6 years (standard deviation 5.0) the marginally de-
reased risk of breast cancer among never-pregnant group, could be
n indicator of the increased risk of breast cancer up to 20years
ollowing a child birth [32]. Contrary to previous studies, our in-
estigation showed women never-pregnant to be slightly protected
gainst melanoma [33].
.4. Strengths and Limitations
The main strength of this study was the population size, includ-
ng over 28,000 incident cancer events with a full registry-based
eproductive history. As our study was nationwide and registry-
ased, our study was unaffected by recall-bias. Furthermore, the
ational Danish registries have previously been shown to have a
igh degree of validity, both for disease and pregnancy. The diag-
osis codes for miscarriage, have been validated to have a positive
redictive value of 97.4% [34].
Limitations include the underreporting of pregnancy losses, as
ome women do not seek hospital aid when experiencing early
regnancy loss. However, the underreporting is expected to be
qual among cases and controls. Variables of potential interest
uch as smoking and body mass index were incomplete. To ac-
ount for this limitation, we provided a sensitivity analysis for
ung cancer outcome, restricted to those with smoking data and
djusted for this possible confounder (Supplementary Table S3).
ikewise, the outcome of gastro-intestinal cancer was adjusted for
ody mass index >30 (Supplementary Table S6). Although our
tudy was large, some exposures and outcomes were rare, and the
dds ratios consequently with wide confidence limits. We chose to
ocus our analyses on cancers after the age of 40 to ensure a near
omplete pregnancy history before a possible outcome of interest
ccurred, however this choice could limit the finding of a possiblessociation between pregnancy loss and specific cancers at younger
ge.
In conclusion, our findings did not indicate an association be-
ween pregnancy loss and later cancer. For women already suffer-
ng from the burden of experiencing multiple pregnancy losses, our
ndings based on a large and unselected data material is impor-
ant. Future research may focus on other long-term health risks for
omen experiencing recurrent pregnancy loss.
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